Key result
Overexpression of Prepro-ET-1 significantly increased ET-1 secretion and reduced eNOS expression and NO generation in fetal pulmonary artery endothelial cells through PKCδ-mediated activation of STAT3.
Why the study?
Does overexpression of Prepro-ET-1 decrease eNOS expression and NO generation in fetal pulmonary artery endothelial cells?
Does overexpression of Prepro-ET-1 decrease eNOS expression and NO generation in fetal pulmonary artery endothelial cells?
ET-1 reduces eNOS expression and NO generation in fetal pulmonary artery endothelial cells through PKCdelta-mediated activation of STAT3, providing a molecular mechanism for endothelial dysfunction in persistent pulmonary hypertension of the newborn.
Supports ET-1 pathway in ovine fetal endothelial dysfunction; leaves open human PPHN relevance pending in vivo validation.
In an ovine model of persistent pulmonary hypertension of the newborn (PPHN), endothelin-1 (ET-1) expression is increased, while endothelial nitric oxide synthase (eNOS) expression is decreased. However, the molecular mechanisms by which ET-1 attenuates eNOS expression in endothelial cells are not completely understood. Thus, the goal of this study was to determine if the overexpression of ET-1 decreases eNOS expression in pulmonary arterial endothelial cells isolated from fetal lambs. To increase the ET-1 expression, cells were transfected with a plasmid coding for Prepro-ET-1, a precursor of ET-1. After overexpression of Prepro-ET-1, ET-1 levels in the culture medium were significantly increased (control = 805.3 +/- 69.8; Prepro-ET-1 overexpression = 1351 +/- 127.9). eNOS promoter activity, protein levels, and NO generation were all significantly decreased by the overexpression of Prepro-ET-1. The decrease in transcription correlated with increased activity of protein kinase Cdelta (PKCdelta) and STAT3. Further, DNA binding activity of STAT3 was also increased by Prepro-ET-1 overexpression. The increase in STAT3 activity and decrease in eNOS promoter activity were inhibited by the overexpression of dominant negative mutants of PKCdelta or STAT3. Further, a 2 bp mutation in the STAT3 binding site in the eNOS promoter inhibited STAT3 binding and led to enhanced promoter activity in the presence of Prepro-ET-1 overexpression. In conclusion, ET-1 secretion is increased by Prepro-ET-1 overexpression. This results in activation of PKCdelta, which phosphorylates STAT3, increasing its binding to the eNOS promoter. This in turn decreases eNOS promoter activity, protein levels, and NO production. Thus, ET-1 can reduce eNOS expression and NO generation in fetal pulmonary artery endothelial cells through PKCdelta-mediated activation of STAT3.
No takes yet. Share an insight, caveat, or question.
Sud et al. (2009) studied Persistent pulmonary hypertension of the newborn (PPHN). Prepro-ET-1 overexpression vs. Parental vector control was evaluated on ET-1 levels in culture medium (pg/mL) (p=<0.05). Overexpression of Prepro-ET-1 significantly increased ET-1 secretion and reduced eNOS expression and NO generation in fetal pulmonary artery endothelial cells through PKCδ-mediated activation of STAT3.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: